A Feasibility Study of Vorinostat (SAHA) Combined With Isotretinoin and Chemotherapy in Infants With Embryonal Tumors of the Central Nervous System

Trial Profile

A Feasibility Study of Vorinostat (SAHA) Combined With Isotretinoin and Chemotherapy in Infants With Embryonal Tumors of the Central Nervous System

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Dec 2017

At a glance

  • Drugs Vorinostat (Primary) ; Carboplatin; Cisplatin; Cyclophosphamide; Etoposide phosphate; Isotretinoin; Thiotepa; Vincristine
  • Indications Medulloblastoma; Primitive neuroectodermal tumours; Rhabdoid tumour
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 04 May 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Dec 2017.
    • 21 Dec 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Jan 2017, according to ClinicalTrials.gov record.
    • 24 Oct 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top